Kelonia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KLN-1010, an in vivo BCMA CAR-T Therapy for Relapsed and Refractory Multiple Myeloma   

by jtierney | Jan 7, 2026 | Press Releases

U.S. IND represents the second regulatory clearance for KLN-1010 and enables the first multi-center clinical trial in the U.S. for an anti-BCMA in vivo CAR-T program  BOSTON,...

Kelonia Therapeutics Presents First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting  

by jtierney | Dec 9, 2025 | Press Releases

100% MRD-negative response rate in four patients; all remain in response through the longest follow up of 5 months  Favorable toxicity profile with no CRS grade 3 or above and no ICANS  Potent CAR-T expansion from a single, an off-the-shelf infusion without...

Kelonia Therapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data from in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting

by jtierney | Nov 24, 2025 | Press Releases

Early results from the Phase 1 inMMyCAR™ study demonstrate ongoing MRD-negative responses in all patients with a tolerable safety profile  Robust CAR-T cell expansion occurred in the absence of preparative chemotherapy  Persistent, memory CAR-T cells in all...

Kelonia Therapeutics Enters into Strategic Collaboration with Johnson & Johnson to Advance in vivo CAR-T Therapies

by jtierney | Nov 5, 2025 | Press Releases

Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a strategic collaboration with Johnson & Johnson* to advance the discovery of novel in vivo CAR-T cell therapies. The collaboration aims to develop...

Kelonia Therapeutics Doses First Patient in Phase 1 inMMyCAR Study Evaluating in vivo CAR T-Cell Therapy for Relapsed and Refractory Multiple Myeloma

by rob@robmaguiredesigns.com | Aug 19, 2025 | Press Releases

KLN-1010 is the first anti-BCMA in vivo CAR-T program studied in a multi-center clinical trial KLN-1010 is administered directly to patients without apheresis, ex vivo manufacturing or lymphodepletion BOSTON–Kelonia Therapeutics, Inc., a biotech company...

Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting

by rob@robmaguiredesigns.com | May 9, 2025 | Press Releases

BOSTON, Mass., May 9, 2025 – Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced new preclinical data of its in vivo Gene Placement System (iGPS®) will be highlighted at the...